Monthly update - July 2024

Stock markets increased slightly in July with the world index up 1.7 percent, measured in US dollars. A significant rotation from former stock market winners, mainly in technology, to value stocks and smaller companies was an important phenomenon during the month. The technology companies’ reports indicated slightly lower growth momentum, while smaller companies on the other hand, rose sharply with the US smaller companies index, Russell 2000, up 10 percent during July, measured in US dollars. Investors in smaller companies seemed to anticipate better financing opportunities when the central banks’ key interest rates looked set to be cut in the fall.

Tension increased

However, the broader stock market noted an increased risk that the US central bank, the Fed, would not cut interest rates quickly enough. In addition, macro data were generally somewhat weaker than expected during the month and consumer demand appeared to be slowing down. On top of this the labor market showed several signs of weaker demand. The consumer price index pointed to continued falling inflation, which with the persistently high Fed interest rates meant an even more restrictive monetary policy. The nervousness of investors increased, and many were forced to reduce the risk in their portfolios, not least those who had financed shares through loans in the appreciating Japanese yen.

Waiting for an interest rate cut

The US Federal Reserve’s chairman, Jerome Powell, confirmed, in connection with the Fed meeting at the end of July, that the bank was leaning towards one or more interest rate cuts this fall, as inflation had fallen, and the labor market looked likely to soften. They did, however, want to see further confirmation that the lower inflation rate was being maintained before the Fed funds rate was cut. Many observers believed that the Fed, with Powell at the helm, was already too late with a first interest rate cut and that the risk of a ”hard landing” had therefore increased. Risks in the stock markets were thus judged to have risen and higher volatility marked the end of the month.

A hot (political) summer month

It was an eventful and important month in politics. The most important development was likely that, with the new support package from the US, Ukraine appeared to have better opportunities to defend itself in the war against Russia. The country began to destroy energy infrastructure inside Russia, which is critical for effective Russian warfare. Israel’s attacks on high-ranking officials within Hezbollah and Hamas, inside Lebanon and Iran respectively, were considered likely to lead to retaliatory attacks against Israel and the situation became very tense. Although an all-out war is still not seen as being very likely, many are concerned because it would be extremely risky for world peace.

The elections in England and France pointed in completely different directions. In England, the people voted in a Labor government for the first time in 14 years and tax increases are to be expected. In France, the right wing advanced strongly. However, they did not reach a level of major influence since the other parties effectively prevented LePen’s National Assembly from getting the full impact of their votes through electoral cooperation in the elections’ second round. Many worry that France, with this weak parliamentary situation, is heading for even higher budget deficits and that this could lead to a new crisis for the euro.

In the US, President Biden renounced his candidacy and Vice President Kamala Harris quickly succeeded in establishing herself as the Democrats’ presidential candidate, before the Democratic convention had the opportunity to discuss the issue. The Democrats were thus given a chance to quickly restart their election campaign with the US elections described by many observers as now having become much more even.

The healthcare sector in the background

The eventful month did not appear to have any immediate effect on the fundamentals of the companies in the healthcare sector. Healthcare issues were still in the background in the political debate and there was no indication that Harris would deviate significantly from the various positions of the Biden administration, if she were to be elected president.

OUTLOOK

Higher volatility and weakness in the stock market, not least in the tech sector, is now a fact. After a long period of restrictive monetary policy, there is a high degree of uncertainty about the US labor market. Long-term interest rates are falling sharply as a result of lower risk appetite, the increased risk of recession, and lower inflation. However, interest in smaller companies seems to have revived. Smaller companies are particularly important in the biotechnology subsector, as well as in segments of the medical technology, and the healthcare services subsectors.

It is unclear whether this renewed interest can last in a scenario where there are more and stronger signs of the economy’s weakening. Ideal conditions on the stock market for smaller companies are falling interest rates resulting from falling inflation, but not as a consequence of a weakened labor market or an increased risk of recession. A possible recession would be a threat to many companies. The players in the healthcare sector that are most likely to best cope with such a situation ought to be the major pharmaceutical companies and the large healthcare companies, both with stable cash flows and rising dividend capacity.

Critical months ahead

The next few months will be particularly critical, and outcomes may vary significantly depending on upcoming macro statistics regarding jobless claims and new employments, in particular. We believe in continued good fundamental prospects for the sector’s companies in all four subsectors, but continued rising volatility in the stock market could lead to profit-taking, despite mainly good reports for the first half of the year, mostly optimistic forecasts for the rest of the year and, in our view, well-substantiated values. We would like to highlight that the sub-sectors of the healthcare sector, on average, tend to perform well in the twelve months following an interest rate cut in the US. However volatility is here, and we can count on the near future to deliver a few surprises.

Andra nyheter från oss

Alla

Direkt

Finwire

Okategoriserat

Rhenman & Partners

Monthly comment (Apr 25): Healthcare sector impacted by political uncertainty

Monthly summary – March 2025: a volatile month, again impacted by the macro-economic and political backdrop

Rhenman Healthcare Equity L/S minskade 13,61 procent i mars – volatilt för hälsovårdssektorn

Monthly summary – February 2025: Sentiment turned sour in February

Rhenman Healthcare Equity L/S sjönk 4,52 procent i februari – politisk osäkerhet pressade marknaden

Rhenman & Partners strengthens its Operations Team

Rhenman & Partners förstärker sitt Operationsteam

Monthly comment – January 2025: All sectors except technology closing in positive territory

Rhenman Healthcare Equity L/S ökade 8,41 procent i januari – stark rotation mot hälsovård

Monthly comment – December 2024

Rhenman Healthcare Equity L/S minskade 10,48 procent i december – tungt avslut på 2024

Monthly summary – November 2024: Once the election results were in, focus shifted torwards likely economic implications

Rhenman Healthcare Equity L/S ökade 1,67 procent i november – volatilt efter valet i USA

How is the healthcare sector affected by the US election results?

Hur påverkas en av världens mest reglerade sektorer av valutgången i USA?

Rhenman Healthcare Equity L/S minskade 2,00 procent i oktober – fokus på rapportperiod och USA-val

October 2024 summary – Initital focus on the earnings season switched to focus on election outcomes

Rhenman Healthcare Equity L/S föll 3,53 procent i september – positiv långsiktig utsikt trots volatil marknad

Monthly summary – September 2024

Rhenman & Partners strengthens its Investor Relations team further

Rhenman & Partners förstärker sitt Investor Relations-team ytterligare

Monthly summary – August 2024

Rhenman Healthcare Equity L/S ökade 3,35 procent i augusti – optimistisk syn på andra halvåret

Rhenman & Partners förstärker investeringsteamet – ytterligare en portföljförvaltare inom biopharma

Rhenman & Partners strengthens investment team – hires additional biopharma PM

Rhenman Healthcare Equity L/S ökade 5,26 procent i juli – tydlig sektorrotation

Rhenman Healthcare Equity L/S ökade 1,42 procent i juni – stark månad för aktiemarknaden

Monthly summary – June 2024

Rhenman & Partners celebrates 15 years

Rhenman Healthcare Equity L/S föll 1,29 procent i maj – ser positivt på andra halvåret

Monthly summary – May 2024

Rhenman Healthcare Equity L/S minskade 2,57 procent i april – svag utveckling för de flesta delsektorer

Monthly summary – April

Rhenman Healthcare Equity L/S ökade 5,86 procent i mars – starka bidrag från medicinteknik

Monthly summary – March 2024

Rhenman & Partners strengthens its investor relations team

Rhenman & Partners förstärker Investor Relations

Rhenman Healthcare Equity L/S ökade 4,45 procent i februari – stark månad för bioteknik

Monthly summary – February 2024

Rhenman Healthcare Equity ökade 6,17 procent i januari – Shockwave och Eli Lilly bidrog positivt

Monthly summary – January 2024

Monthly summary – December 2023

Rhenman Healthcare Equity L/S ökade 5,43 procent i december – Cytokinetics bidrog positivt till utvecklingen

Monthly summary – November 2023

Monthly update – November 2023

Rhenman Healthcare Equity ökade 3,58 procent i november – Immunogen bidrog positivt

Monthly summary – October

Rhenman Healthcare Equity minskade 3,03 procent i oktober – två uppköp under månaden

The complex reality of investing in Biopharma

Rhenman Healthcare Equity minskade 6,07 procent i september – Immunovant steg kraftigt efter goda resultat

Monthly summary – September

Rhenman Healthcare Equity ökade 2,91 procent i augusti – Eli Lilly och Novo Nordisk i blickfånget

MONTHLY SUMMARY – AUGUST 2023

Rhenman Healthcare Equity minskade 4,01 procent i juli – Apellis Pharmaceuticals tyngde utvecklingen

Rhenman Healthcare Equity L/S ökade 2,65 procent i juni – ökar allokeringen mot tryggare bolag

Monthly summary – June 2023

Susanna Urdmark lämnar Rhenman & Partners

Susanna Urdmark to leave Rhenman & Partners

Susanna Urdmark lämnar Rhenman & Partners

Rhenman Healthcare Equity ökade 3,24 procent i maj – Immunogen bidrog positivt till utvecklingen

Dan Hoflund ny styrelseledamot för Rhenman & Partners Asset Management

Rhenman Healthcare Equity L/S ökade 3,83 procent i april – Tenet Health utvecklades starkt

Monthly summary – April 2023

Rhenman Healthcare Equity L/S minskade 1,02 procent i mars – Novo Nordisk aktiekurs fortsätter stiga

Monthly summary – March 2023

Lars Wedenborn ny styrelseledamot för Rhenman & Partners Asset Management

Lars Wedenborn – ny styrelseledamot Rhenman & Partners Asset Management

Rhenman Healthcare Equity L/S minskade 4,42 procent i februari – rekyl på aktiemarknaderna under februari

Monthly summary – February 2023

Rhenman Healthcare Equity ökade 3,75 procent i januari – Revance Therapeutics och Tenet Healthcare bidrog positivt (uppdatering)

Rhenman Healthcare Equity ökade 3,75 procent i januari – Revance Therapeutics och Tenet Healthcare bidrog positivt

Monthly summary – January 2023

Rhenman Healthcare Equity minskade 4,76 procent i december – Horizon Therapeutics främsta bidragsgivare

Monthly summary – December 2022

Rhenman & Partners strengthens its investment team with a biopharma analyst

Rhenman & Partners förstärker sitt investeringsteam med biopharmananlytiker

Rhenman Healthcare Equity L/S ökade 2,51 procent i november – Abiomed och Horizon Health bidrog positivt

Summary – November 2022

Rhenman Healthcare Equity L/S: +5,7% i oktober, flera faktorer pekar på hyfsad vinter men makrorisker ska ej underskattas – förvaltare

Summary – October 2022

Rhenman Healthcare Equity L/S ökade 5,68 procent i oktober – lyfter fram potentiell presidentcykeleffekt

Rhenman Healthcare Equity L/S: -1,5% i september, investmentbanker sänkte Jazz Pharmaceuticals och Vitrolife (R)

Rhenman Healthcare Equity L/S minskade 1,5 procent i september – Revance Therapeutics och Regeneron Pharmaceuticals främsta bidragsgivare

Teresa Isele ny vd för Rhenman & Partners Asset Management

Teresa Isele ny VD för Rhenman & Partners Asset Management AB

Teresa Isele to be the new CEO of Rhenman & Partners Asset Management AB

Rhenman Healthcare Equity L/S: +1,7% i augusti, förvaltare positiva till amerikansk läkemedelsreform

Rhenman Healthcare Equity L/S ökade 1,70 procent i augusti – biotekniksektorn gynnade utvecklingen

Rhenman Healthcare Equity L/S RC1 SEK: +5,4% i juli, ser på uppgångarna med försiktighet

Rhenman Healthcare Equity L/S ökade 5,39 procent i juli – fortsatt försiktig inställning

Rhenman Healthcare Equity L/S: +4,5% i juni, ser inte läge att öka aktieexponering trots viss ljusning.

Rhenman Healthcare Equity L/S ökade 4,50 procent i juni – stark återhämtning från små- och medelstora bioteknikbolag

Rhenman Healthcare Equity L/S minskade 3,19 procent i maj – stora läkemedelsbolag bidrog positivt

RHENMAN HEALTHCARE EQUITY L/S: -3,2% I MAJ, BUD PÅ BIOHAVEN

Rhenman & Partners fortsätter att expandera – sök rollen som biopharma-analytiker

Rhenman & Partners winner of Refinitiv Lipper Fund Awards Nordics

Rhenman & Partners vinnare av internationellt fondpris

Lediga tjänster inom Investor Relations

Rhenman Healthcare Equity L/S: -4,9% i april, tyngdpunkt på stora bolag för tillfället

Rhenman Healthcare Equity L/S minskade 4,93 procent i april – läkemedelsbolag minst påverkade av ökad global osäkerhet

SV